Comparative Pharmacology
Head-to-head clinical analysis: REVUFORJ versus VONJO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVUFORJ versus VONJO.
REVUFORJ vs VONJO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
Pacritinib is a Janus kinase 2 (JAK2) and interleukin-1 receptor-associated kinase 1 (IRAK1) inhibitor. It inhibits JAK2 and mutant JAK2V617F, reducing cytokine signaling and proliferation of malignant cells.
Oral, 500 mg twice daily.
400 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Terminal elimination half-life approximately 40–60 hours; allows once-daily dosing. Steady-state achieved in 8–14 days.
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Primarily metabolized by the liver via CYP3A4 and CYP2C8; ~90% eliminated in feces as metabolites, ~10% in urine as unchanged drug and metabolites.
Category C
Category C
JAK Inhibitor
JAK Inhibitor